Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of LOXO-783 in Healthy Adults
NCT06028425Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LOXO-783 in breast cancer and solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration and Area Under the Concentration-Time Curve. Started Sep 2023; status: completed.
02
Drugs
LOXO-783
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06028425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028425.